We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Should we consider MMF therapy after rituximab for nephrotic syndrome?
- Authors
Filler, Guido; Huang, Shih-Han; Sharma, Ajay
- Abstract
The management of steroid-dependent nephrotic syndrome, especially in patients who have failed to respond to cytotoxic drugs, such as cyclophosphamide, remains challenging. Rituximab represents a new (off-label) therapeutic option. In a significant portion of patients, it has a short serum half-life following the recovery of CD20-positive cells. The addition of mycophenolate mofetil (MMF) as a maintenance therapy is also an attractive option, but one which requires testing in a prospective randomized clinical trial with therapeutic drug monitoring and mechanistic ancillary studies.
- Subjects
STEROID drugs; IMMUNOSUPPRESSIVE agents; RITUXIMAB; GRAFT rejection prevention; DRUG resistance; NEPHROTIC syndrome; HEALTH outcome assessment; TREATMENT effectiveness; CHILDREN; THERAPEUTICS
- Publication
Pediatric Nephrology, 2011, Vol 26, Issue 10, p1759
- ISSN
0931-041X
- Publication type
Editorial
- DOI
10.1007/s00467-011-1894-x